Article
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
Oncotarget - 4 Apr 2017
Incorvaia Lorena, Passiglia Francesc, Rizzo Sergio, Galvano Antonio, Listì Angela, Barraco Nadia, Maragliano Rossella, Calò Valentina, Natoli Clara, Ciaccio Marcello, Bazan Viviana, Russo Antonio
Abstract excerpt
Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been investigated in ovarian and breast cancer, showing promising efficacy in BRCA-mutated patients. Recently clinical studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.